Orexigen Therapeutics (OREX) Misses Q2 EPS by 1c

Orexigen Therapeutics Reports Financial and Business Results for the Second Quarter Ended June 30, 2015

SAN DIEGO, Aug. 6, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced business and financial results for the second quarter ended June 30, 2015.

"We are very pleased with the strong growth of Contrave® prescription volumes, driven by a product profile that is resonating with physicians and patients and by the steady, market-leading share of voice provided by Takeda," said Mike Narachi, CEO of Orexigen. 

Narachi continued: "Today we also announced a favorable, win-win resolution to the dispute with Takeda, a new distributorship agreement for South Korea with... More

Orexigen Announces Korean Distributorship Agreement with Kwang Dong Pharmaceutical Company

SAN DIEGO, Aug. 6, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that wholly-owned subsidiary Orexigen Therapeutics Ireland Ltd. and Kwang Dong Pharmaceutical Company, Ltd. have executed a distributorship agreement for South Korea for Contrave® (naltrexone HCl / bupropion HCl extended release) monotherapy for weight management in overweight or obese adult patients. Under the terms of the agreement, Kwang Dong will be responsible for seeking regulatory approval and for all commercialization activity and expenses. Orexigen will supply Contrave tablets to Kwang Dong for a $7 million upfront payment, approximately 35 40% of net sales, potential... More

Orexigen and Takeda Announce an Amended and Restated Collaboration Agreement

SAN DIEGO and DEERFIELD, Ill., Aug. 6, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) and Takeda Pharmaceutical Company Limited (TYO: 4502) today announced execution of an amended and restated collaboration agreement that resolves all outstanding disputes between the companies and aligns the partnership for the continued long-term success of CONTRAVE.

"CONTRAVE has quickly established itself as the most prescribed branded weight-loss medication in a rapidly growing market. Today, we have reaffirmed our commitment to the success of... More